Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chia-Jen Liu

Showing results (281-290 of 298) with videos related to

Pageof 30
Sort By:
Nature Communications|May 21, 2024
Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasisUdit Singhal, Srinivas Nallandhighal, Jeffrey J Tosoian, et al.
Medicine|July 2, 2015
Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in TaiwanYu-Ting Lee, Chia-Jen Liu, Yu-Wen Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaJacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
The Journal of Clinical Investigation|February 10, 2022
Direct cellular reprogramming enables development of viral T antigen-driven Merkel cell carcinoma in miceMonique E Verhaegen, Paul W Harms, Julia J Van Goor, et al.
American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|March 19, 2024
Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in TaiwanYi-Che Huang, Fei-Yuan Hsiao, Shang-Ting Guan, et al.
JCI Insight|March 22, 2024
ctDNA transiting into urine is ultrashort and facilitates noninvasive liquid biopsy of HPV+ oropharyngeal cancerChandan Bhambhani, Qing Kang, Daniel H Hovelson, et al.
Nature Cancer|January 7, 2021
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myelomaOksana Zavidij, Nicholas J Haradhvala, Tarek H Mouhieddine, et al.
Nature Communications|September 29, 2025
Uncertainty-aware ensemble of foundation models differentiates glioblastoma from its mimicsJunhan Zhao, Shih-Yen Lin, Raphaël Attias, et al.
Pageof 30

Showing results (281-290 of 298) with videos related to

Sort By:
Pageof 30
Nature Communications|May 21, 2024
Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasisUdit Singhal, Srinivas Nallandhighal, Jeffrey J Tosoian, et al.
Medicine|July 2, 2015
Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in TaiwanYu-Ting Lee, Chia-Jen Liu, Yu-Wen Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaJacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
The Journal of Clinical Investigation|February 10, 2022
Direct cellular reprogramming enables development of viral T antigen-driven Merkel cell carcinoma in miceMonique E Verhaegen, Paul W Harms, Julia J Van Goor, et al.
American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|March 19, 2024
Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in TaiwanYi-Che Huang, Fei-Yuan Hsiao, Shang-Ting Guan, et al.
JCI Insight|March 22, 2024
ctDNA transiting into urine is ultrashort and facilitates noninvasive liquid biopsy of HPV+ oropharyngeal cancerChandan Bhambhani, Qing Kang, Daniel H Hovelson, et al.
Nature Cancer|January 7, 2021
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myelomaOksana Zavidij, Nicholas J Haradhvala, Tarek H Mouhieddine, et al.
Nature Communications|September 29, 2025
Uncertainty-aware ensemble of foundation models differentiates glioblastoma from its mimicsJunhan Zhao, Shih-Yen Lin, Raphaël Attias, et al.
Pageof 30